期刊文献+

POCT 在肿瘤标志物检测领域的应用与发展 被引量:1

Application and development of point-of-care testing in domain of tumor markers
原文传递
导出
摘要 恶性肿瘤是我国最常见的导致死亡的疾病。由于病因与发病机制复杂,且缺乏早期诊断的特异性指标,导致诊断和治疗滞后,病死率高。随着基础研究的发展,越来越多提示早期肿瘤存在的特异性标志物被发现,但目前的检测大多依赖于大型医院的专业实验室,耗时长,价格昂贵,给患者在时间和经济上带来诸多困难且在医疗资源匮乏地区难以推广。近期新兴的检验模式POCT发展迅猛,因其设备便携,获得结果迅速,可在社区等基层医疗机构以及经济落后地区开展,有利于人群中肿瘤标志物( TM)的筛查。通过POCT在TM领域的应用,以期实现对肿瘤早发现、早诊断、早治疗,降低死亡率。 Malignant tumors are the most common lethal diseases in China.Because of complexity of etiology and pathogenesis , and the lack of specific markers for early diagnosis , delayed diagnosis and treatment of cancer , the fatality rate is high.With the development of basic research , more and more early specific markers were found , but the current detection mostly depend on the professional laboratories , time-consuming , high price and have a number of inconveniences to patients on time and money.Meanwhile , it′s difficult to extend to zoon of medicine resources deficient.Recently, point-of-care testing (POCT) has been rapidly developed , because of its portability , getting results quickly , can be operated in basic medical units and economic backward areas , so it′s benefit to cancer screening in human.By the application in tumor markers, POCT can be done for the cancer early detection , early diagnosis and early treatment , so then cuts the death rate.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2014年第11期808-811,共4页 Chinese Journal of Laboratory Medicine
基金 国家自然科学基金资助项目(81171546) 浙江省医药卫生平台计划重点资助(2014ZDA018)杭州市医药卫生科技计划项目(20108010) 杭州市科技发展计划项目(20120533Q29)
关键词 肿瘤标记 生物学 床旁诊断化验信息系统 质量控制 Tumor markers,biological Point-of-care systems Quality control
  • 相关文献

参考文献16

  • 1邹雄.肿瘤标志在肿瘤早期诊断中的研究与应用进展[J].中华检验医学杂志,2002,25(2):71-72. 被引量:97
  • 2李福刚,顾敏晔,薛汉阳,徐建新.浅谈POCT技术在检验医学中的应用和发展趋势[J].中华检验医学杂志,2012,35(12):1218-1219. 被引量:10
  • 3Ge S, Ge L, Yan M, et al. A disposable immunosensor device for point-of-care test of tumor marker based on copper-mediated amplification[J]. Biosens Bioelectron, 2013, 43:425-431.
  • 4Kuroki M. Present status and perspectives of tumor markers[J]. Nihon Rinsho, 2005, 63:585-591.
  • 5中华医学会检验分会.2012年POCT的临床应用与建议[J].中华检验医学杂志,2012,35:10-16.
  • 6Shi JF, Canfell K, Lew JB, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China:an epidemiologic and cost-effectiveness modelling study[ Jl. BMC Cancer, 2011, 11:239-257.
  • 7Dey P. Urinary markers of bladder carcinoma[ J]. Clin Chim Acta, 2004, 340:57-65.
  • 8Kitano S, Myers J, Nakamura J, et al. A Novel Fully Automated Molecular Diagnostic System (AMDS) for Colorectal Cancer Mutation Detection [J]. PLoS One, 2013, 8:1-10.
  • 9张腊红,陈兆军.心血管疾病相关指标POCT的现状与发展趋势[J].中华检验医学杂志,2013,36(6):494-497. 被引量:4
  • 10International Organization for Standardization. ISO/DIS 22870, Point-of-care-testing ( POCT)-Requirements for quality and competence [M]. Geneva : ISO, 2004.

二级参考文献62

  • 1Rimer BK 徐从高等(译).肿瘤筛查.癌-肿瘤学原理和实践[M].济南:山东科技出版社,2001.653-667.
  • 2National Committee for Clinical Laboratory Standards. Performance of point-of-care in vitro diagnostic testing AST2-P. Wayne, PA:NCCLS, 1995.
  • 3Academy of Medical Laboratory Science, Association of Clinical Biochemists in Ireland, Irish Medicines Board, et al. Guidelines for Safe and Effective Management and Use of Point of Care Testing. 2007-11-28.
  • 4Clinical and Laboratory Standards Institute. Selection Criteria for Point-of-Care Testing Devices; approved guideline. POCTO9-A. Wayne, PA: CLSI, 2010.
  • 5中华医学会检验分会,卫生部临床检验中心,中华检验医学杂志编辑委员会.潘柏申,尚红,陈文祥.POCT临床应用建议.中华检验医学杂志,2012,35:10-16.
  • 6Anthony OO. Optimizing accuracy and precision for point-of-care tests. Point of Care ,2012,11:26-29.
  • 7Tirimacco R, Glastonbury B, Laurence CO, et al. Development of an accreditation program for Point of Care Testing (PoCT) in general practice. Aust Health Rev, 2011, 35:230-234.
  • 8Bonini P, Plebani M, Ceriotti F, et al. Errors in laboratory medicine. Clin Chem, 2002, 48:691-698.
  • 9Kazmierczak SC. Point-of-care testing quality:some positives but also some negatives. Clin Chem,2011,57 :1219-1220.
  • 10O'Kane MJ, McManus P, McGowan N, et al. Quality error rates in point-of-care testing. Clin Chem, 2011, 57:1267-1271.

共引文献123

同被引文献18

  • 1曾沥琼,杨竹.循环肿瘤细胞在卵巢癌预后中的研究进展[J].医学信息(医学与计算机应用),2014,0(14):604-605. 被引量:2
  • 2黄同海,王正,李富荣.循环肿瘤细胞检测的研究新进展[J].中国肿瘤临床,2007,34(8):476-479. 被引量:15
  • 3zoma I, Zku H. Interaetome mapping using protein mieroarray technology to reconstruct diverse protein networks[J]. Genomics Proteomics Bioinformaties, 2013,11 (1) : 18.
  • 4Krueger P,Nitz C,Foster R,et al. A new small cell lung cancer (SCLC) - specific marker discovered through antigenic subtrac- tion of neuroblastona eells[J]. Cancer Immunol Immunother, 2003,52(6) 367.
  • 5Ashworth TR. A case of carmer in which cells similar to those in the tumours were seen in the blood after death[J]. Medical Journal Australia, 1869,14 = 146.
  • 6Alix-Panabires C, Pantel K. Circulating tumor cells:liquid biop- sy of cancer[J]. Clin Chem, 2013,59(1) = 110.
  • 7Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-doeetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate[J] J Clin Oncol, 2010,28 (9) 1489.
  • 8Miller MC, Doyle GV, Terstappen LW. Significance of circulat- ing tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer[J]. J On- col,2010,2010:617421.
  • 9许晓光,黄海燕,宋朝君,石炳毅,蔡明,李州利,金伯泉.肿瘤细胞表面抗原的单克隆抗体-免疫沉淀筛选法[J].解放军医学杂志,2008,33(11):1348-1351. 被引量:2
  • 10娄加陶,顾军,高春芳,范列英,赵虎,李智,沈霞,孔宪涛,仲人前.蛋白芯片检测肿瘤标志物及其与其他方法的比较[J].检验医学,2009,24(6):466-469. 被引量:11

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部